The ultimate goal of my research is to develop effective strategies for detection and treatment of ovarian and breast cancers, and translate these research findings into the clinic. Specifically, we are interested in (1) Developing strategies to overcome immunosuppression in ovarian and breast cancers; (2) Developing biomimetic nanoparticle platforms for tumour-targeted delivery of RNAi therapeutics; and (3) Understanding the role of exosomes in ovarian cancer progression.

Harnessing the immune system to battle ovarian cancer

Ovarian cancer is the most lethal form of gynaecologic malignancy with 5-year survival rate of only 35-40%. The high recurrence rate presents a major challenge in the clinical management of high grade serous ovarian cancer. While stimulating our own immune system to recognize and attack tumour cells represents an attractive means to facilitate complete elimination of tumours, emerging data suggest that many of the immunotherapy tools have promising but limited effects in ovarian cancer. To address this unmet need, my lab focuses on developing novel strategies to enhance anti-tumour immunity in ovarian cancer. We utilise systems-based approach combined with RNA interference technology to target clinically important immune suppressive factors with the goal of enhancing cytotoxic T-cell functions in ovarian tumours. Ultimately, the ability to effectively stimulate the immune system to attack tumour cells could significantly improve outcomes of women with ovarian cancer. The technology we develop can also be applied for treatment of other cancer types.

Tumour-targeted delivery systems

My lab is focusing on developing clinically translatable tumour-targeted delivery systems for RNAi therapeutics. SiRNA, a short double stranded RNA, represents an attractive means to mediate down-regulation of target genes. Unlike conventional small molecule inhibitors or monoclonal antibodies, siRNA is highly specific to its target and has a much wider clinical applicability as its use is not limited to targeting ligands or kinases. Several early phase trials have reported clinical responses in cancer patients after RNAi therapy. Despite the promise of existing synthetic delivery systems, the reported spleen, liver, and immune-related toxicities in early phase clinical trials must be overcome before RNAi can meet the standards for clinical use. To address this need, we are developing a novel and biocompatible delivery strategy using naturally occurring exosomes that are highly efficient in delivering their cargo to recipient cells. Being natural transporters, exosomes are also less likely to exert toxicity or elicit immune responses.

Role of exosomes in cancer progression

Exosomes are tiny lipid vesicles that can be generated by many cell types in our body. They serve as effective means for cells to communicate with each other, even when they are located remote from each other. Cancer cells, in particular, produce large quantities of exosomes with distinct markers and characteristics. The content of these exosomes highly reflects the characteristics of the cells that generate them. Our lab is interested in understanding the role of exosomes in cancer progression and metastasis.

Positions are available across our research program for undergraduates, honours students, PhD students, and postdoctoral fellows. If you are interested in joining our lab, please contact Dr Wu.

Potential research projects include, but not limited to:

Theme 1: Harnessing the immune system to battle ovarian and breast cancers

  • Investigate the mechanisms by which microRNA enhances anti-tumour immunity in ovarian cancer
  • Overcoming endothelial barriers for T-cell trafficking in ovarian and triple negative breast cancers

Theme 2: Developing clinically translatable nano-systems to break down immune barriers

  • Developing exosomal nanoparticle system to directly engineer T-cells in vivo
  • Using exosomal nanoparticles to generate an effective anti-tumour immune response

Theme 3: Understanding the role of exosomes in cancer progression

  • Understanding the role of exosomes in cancer progression and metastasis

Original research articles

Court KA, Hatakeyama H, Wu SY, et al. HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. Molecular Cancer Therapeutics 2017, 16(5):966-976.

Wu, S.Y., Rupaimoole, R., Shen, F., et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications 2016, 7:111169.

Hatakeyama, H., Wu, S.Y., Lyons, Y.A., et al. Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers. Cell Reports 2016, 17(6):1621-31.

Miyake TM, Pradeep S, Wu SY, et al. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research 2015, 21(14):3286-97.

Wu, S.Y., Yang, X.B., Gharpure, K., et al. 2’-OMe-phosphorodithioate modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications 2014, 5, 3459.

Rupaimoole, R., Wu, S.Y., Pradeep, S., et al. Hypoxia mediated downregulation of miRNA biogenesis leads to increased tumor progression. Nature Communications 2014, 5:5202.

Pradeep, S., Kim, S.W., Wu, S.Y., et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 2014, 26(1):77-91.

Pecot, C.V., Wu, S.Y., Bellister, S., et al. Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Molecular Cancer Therapeutics 2014, 13(12):2876-85.

Wu, S.Y., Chang, H.I., Burgess, M., et al. Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. Journal of Controlled Release 2011, 155(3):418-26.

Wu, S.Y., Singhania, A., Burgess, M., et al. Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models.  Gene Therapy 2011, 18(1): 14-22.

Singhania, A.*, Wu, S.Y.*, McMillan, N.A.J. Effective delivery of PEGylated siRNA-containing lipoplexes to extraperitoneal tumours following intraperitoneal administration. Journal of Drug Delivery 2011, e192562.

*These authors contributed equally to the work.

Wu, S.Y., Putral, L.N., Liang M., et al. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharmaceutical Research 2009, 26(3):512-22.

Wu, S., Campbell, C., Koda, Y., et al. Investigation of the route of absorption of lipid and sugar modified Leu-enkephalin analogues and their enzymatic stability using the Caco-2 cell monolayer system. Medicinal Chemistry 2006, 2(2):203-11.

Review articles

Yang M, Wu, SY. The advances and challenges in utilizing exosomes for delivering cancer therapeutics. Front Pharmacol. 2018, 9:735.

Lyons, Y., Wu, S.Y., Overwijk, W.W., et al. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precision Oncology 2017, 1:Article 26.

Gharpure, K., Wu, S.Y., Li, C., et al. Nanotechnology: Future of oncotherapy. Clinical Cancer Research 2015, 21(14):3121-30.

Wu, S.Y.; Lopez-Berestein, G.; Calin, G.A.; et al. RNAi therapeutics: Drugging the undruggable. Science Translational Medicine 2014, 6:240ps7.

Hua, S.; Wu, S.Y. The use of lipid-based nanocarriers for targeted pain therapies. Frontiers in Neuropharmacology 2013, 4: 143.

Wu, S.Y. and McMillan N.A.J. Lipidic systems for in vivo siRNA delivery. American Association of Pharmaceutical Scientists Journal 2009, 11(4):639-52.

Editorials/Commentary/Book Chapters

Hatakeyama, H., Wu, S.Y., Mangala, L.S., et al. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 2016,1402:189-97.

McCaskill, J.L., Wu, S., Khairuddin, N., et al. Lowering the siRNA delivery barrier: Alginate Scaffolds and Immune stimulation. In: Peer D, editor. Nanotechnology for delivery of Therapeutic Nucleic Acids. Pan Stanford Publishing Pte. Ltd. pp. 193-216 (2013).

Wu, S.Y. Cancer therapy hits its target. Australasian Science, 2010 April, p28-30.

  • 2018-2020    Cancer Institute NSW Career Development Fellowship - Targeting the “undruggable”: Re-activating anti-tumour   immunity by silencing N-MYC in ovarian cancer and neuroblastoma (Declined, due to relocation to Brisbane)
  • 2017-2018    National Institute of Health (NIH) R35 Maximizing Investigators’ Research Award - In vivo genetic engineering of T-cells for treatment of human diseases.
  • 2017-2018    Australian Ovarian Cancer Research Foundation - Re-activating anti-tumour immunity by targeting N-MYC-Let7 axis in ovarian cancer.
  • 2017-2024    National Institute of Health (NIH) R35 - Harnessing the power of exosomes for non-coding RNA delivery.
  • 2016-2019    Ovarian Cancer Research Fund Alliance The Liz Tilberis Early Career Award - Re-activating anti-tumor immunity using non-coding RNAs.
  • 2016-2017    Colleen’s Dream Foundation Pilot Study Grant - Using exosomes for detection of ovarian cancer.
  • 2015             Texas Center for Cancer Nanomedicine Pilot study grant - Development of biomimetic nanosystems for delivering miRNAs for cancer treatment.
  • 2014-2017    Foundation for Women’s Cancer - Caring Together, NY Ovarian Cancer Research Grant
  • 2013-2015    Cancer Prevention Research Institute of Texas Keck Computational Cancer Biology Postdoctoral Fellowship
  • 2013-2014    Texas Center for Cancer Nanomedicine Postdoc Research Award - A biomimetic bi-functional controlled release delivery platform for cancer treatment
  • 2011-2014    Cancer Prevention Research Institute of Texas TRIUMPH (Translational Research in Multi-Disciplinary Program) Postdoctoral Fellowship
  • 2011-2013    Ovarian Cancer Research Fund Ann Schreiber Mentored Investigator Grant - Novel anti-angiogenic strategies for ovarian cancer treatment.
  • 2006-2009    NHMRC Postgraduate Scholarship - Delivery of siRNA for cancer treatment.

Group Head


Find out more about our research environment and how to apply to do a short or long-term research project with us.